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Abstract There is a common perception that excess adiposi-
ty, commonly approximated by body mass index (BMI), is
associated with reduced cancer survival. A number of studies
have emerged challenging this by demonstrating that over-
weight and early obese states are associated with improved
survival. This finding is termed the Bobesity paradox^ and is
well recognized in the cardio-metabolic literature but less so in
oncology. Here, we summarize the epidemiological findings
related to the obesity paradox in cancer. Our review highlights
that many observations of the obesity paradox in cancer reflect
methodological mechanisms including the crudeness of BMI
as an obesity measure, confounding, detection bias, reverse
causality, and a specific form of the selection bias, known as
collider bias. It is imperative for the oncologist to interpret the
observation of the obesity paradox against the above method-
ological framework and avoid the misinterpretation that being
obese might be Bgood^ or Bprotective^ for cancer patients.
Keywords Bodymass index . Excess weight . Adiposity .
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Introduction
Excess body adiposity is a major global public health prob-
lem, with 67 % of the US, 63 % of the UK, and 64 % of
Australia’s population being classified as overweight or obese,
by body mass index (BMI) criteria, in 2014 [1]. A report from
the World Cancer Research Fund (WCRF) [2], and a system-
atic review with standardized meta-analysis from one of the
present authors [3], established, approximately a decade ago,
that elevated BMI is associated with increased cancer inci-
dence for several common adult cancer types. There are now
ten established obesity-related cancers listed by the WCRF,
including post-menopausal breast, endometrial, ovarian, ad-
vanced prostate, colorectal, renal, pancreatic, liver, and gall-
bladder cancers and esophageal adenocarcinoma. There is a
common perception that, compared with normal-weight pa-
tients, elevated BMI is also associated with poorer prognosis
after cancer diagnosis. This certainly is observed in systematic
reviews of the literature among women with breast cancer [4]
and forms a key rationale for weight management recommen-
dations among cancer survivors, endorsed by clinical guide-
lines, for example, by the American Society of Clinical
Oncology [5], with similar recommendations from the
American Cancer Society [6] and European Society for
Medical Oncology [7].
However, a number of isolated historic studies [8–10] and
an emerging number of recent studies [11–15] have observed
that among patients with cancer, elevated BMI is associated
with improved survival compared with normal-weight pa-
tients. The surprising nature of this finding suggests the exis-
tence of an Bobesity paradox^. This phenomenon is well de-
scribed in the cardiovascular and metabolic literature [16–21]
but less well appreciated in oncology. The repeated observa-
tion of the obesity paradox has spawned research that attempts
to explain its occurrence. Posited explanations range from
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methodological (observed associations that contradict under-
lying causality due to confounding and bias) to clinical (seek-
ing mechanistic explanations for obesity acting protectively in
specific populations). In this review, we first explain what the
obesity paradox is; summarize the current epidemiological
findings for the association between overweight or obese sta-
tus at cancer diagnosis and subsequent survival; review clin-
ical and methodological explanations for the obesity paradox;
and conclude with clinical implications and recommendations
for further research.
What Is the Obesity Paradox?
A BMI of 22.5 kg/m2 has been widely accepted as a mid-
reference point for normal weight [22]. The obesity paradox
occurs where the risk of outcome, typically mortality, is sig-
nificantly reduced for BMI values above this referent, where
an increased risk is expected. At very high BMI values, risk
either returns to unity or is increased as illustrated in Fig. 1.
Epidemiological Evidence
There have been mixed findings in incident cancer popula-
tions where there has been exploration for the obesity para-
dox, with the paradox being observed in some studies [8–11,
13–15, 23], but not in all [24–26]. Consequently, there have
been attempts to unify the conflicting results in the literature
with systematic reviews on adiposity and cancer survival
[27–30] but with inconsistent summaries.
The obesity paradox has been observed in different cancer
settings including, for example, in patients with colorectal
cancer undergoing surgery [11]; patients with renal cancer
undergoing surgery [10, 12]; patients with colorectal metasta-
ses undergoing liver resection [13]; elderly patients with acute
myeloid leukemia [14]; and patients with lymphoma undergo-
ing autologous hematopoietic cell transplantation [9]. The
obesity paradox is not limited to non-metastatic disease and
has been observed in a study of 4010 Taiwanese patients
where the most common metastases were the lungs, liver,
brain, and bone, requiring radiotherapy [15], and the hazard
ratios decreased across BMI categories (overweight: HR 0.84
and obese: HR 0.67).
General Points on Interpretation
Given the variations in study findings, there is a need to have
an initial framework to interpret whether the obesity paradox
is a true or artificial association. There are two broad princi-
ples to consider in the study characteristics: (i) when (in rela-
tion to cancer diagnosis) BMI was determined and (ii) the age
of the participants under study.
When BMI was determined is relevant. The recent WCRF
report on the effect of risk factors on survival among women
with breast cancer added a very useful classification—namely,
determination of BMI either at pre-, peri-, or post-diagnosis
(the later typically 12 months after the initial treatment) of
cancer [31]. From these, different patterns of associations
emerge. In a meta-analysis of 29 studies evaluating the impact
of BMI on survival in patients with colorectal cancer,Wu et al.
[30] observed that increasing pre-diagnosis BMI prognosticat-
ed for a poor survival but that post-treatment overweight was
associated with improved survival, i.e., the obesity paradox.
Table 1 demonstrates that the obesity paradox can be illustrat-
ed in all three settings of pre- [32], peri- [15], and post-
diagnosis [11] for different cancer types.
Age is an additional attribute for consideration. For exam-
ple, studies involving patients with leukemia are challenging
to interpret due to the great age ranges of included individuals.
Navarro and colleagues [33] showed that in over 4000 adults
with acute myeloid leukemia under marrow transplantation,
the obesity paradox was absent in young patients but present
in those over age 60. Similar findings were noted by Brunner
and colleagues, in a treatment cohort of adults with AML aged
greater than 60 years [14].
Explanations for the Obesity Paradox
Determining whether the obesity paradox is a causal phenom-
enon among patients with cancer is clinically relevant, as it
informs weight management strategies among cancer
Fig. 1 An illustration of the obesity paradox. The vertical axis represents
hazard ratio of mortality (log scale), compared with the baseline BMI of
22.5 kg/m2. The plot represents a population in which the obesity paradox
is observed, since the hazard ratio is below 1 in the overweight and obese
range. The 95 % confidence intervals are shown with dashed lines
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survivors. There are many potential causes of the obesity par-
adox, and understanding these is central to clinical implica-
tions. These are grouped into two broad categories [16]: the
first is methodological and reflects spurious or artificial asso-
ciations; the second is clinical and potentially reflects true
associations and is clinically useful.
Methodological Explanations
BMI as an Inadequate Measure of Adiposity
BMI is commonly used as an approximation of general body
adiposity in studies that have observed the obesity paradox.
BMI is appealing as it is routinely measured in primary care
and hospital settings and there are well-defined criteria for
normal, overweight, and obese categories. However, BMI is
a relatively crude measure of body adiposity and body com-
position and does not differentiate between lean mass and fat
mass. In turn, body composition varies with age, sex, and
ethnicity [22], such that there are currently no specific age-
gender-ethnicity indices to define obesity in a standardized
manner. Thus, for example, in a cancer population, over-
weight individuals (defined by BMI) might be younger with
high muscle mass (compared with normal weight), explaining
their better outcome compared with normal weight.
The paradox might not exist if alternate measures of body
composition or adipose tissue were used. Thus, for example,
we found no examples of studies in patients with cancer dem-
onstrating the obesity paradox when anthropometric measures
other than BMI or body composition indices were used.
Alternate indices include measurements such as waist circum-
ference, waist to hip ratio, skinfold, and body composition
assessment techniques such as dual-energy X-ray absorptiom-
etry, CT, and MRI, and quantify different body fat compo-
nents such as subcutaneous adipose tissue (SAT) and visceral
adipose tissue (VAT) [34, 35]. Gonzalez and colleagues [36]
recently explored this hypothesis and showed that the obesity
paradox was present in 175 patients with various cancers
(breast, gynecological, head and neck, lung, and gastrointes-
tinal) when BMI was the exposure of interest but disappeared
when obesity was defined using fat mass index and fat-free
mass index.
Confounding
Confounding occurs when there are variables that are associ-
ated with both the outcome (death) and the exposure (obesity)
and are not on the causal pathway between them. A common
example is smoking, where BMI values are generally lower in
current smokers than in never smokers. Other examples in-
clude deprivation, socioeconomic status, physical activity, and
diet. It is difficult to adjust for all confounding factors, as
many are unobserved. Measurement error may lead to
incomplete removal of confounding, and to avoid this in the
smoking context, some studies exclude smokers from their
analysis [37], but usually, this is at the cost of disregarding a
large proportion of the sample. Another approach would be to
quantify exposure more accurately, for example, in terms of
smoking duration and intensity using pack-years variables or
cumulative lifetime exposure.
An example of confounding as a source of a spurious obe-
sity paradox is illustrated in clinical treatment series reported
by Hakimi and colleagues [12] in 2119 patients with renal cell
carcinoma undergoing surgical resection at Memorial Sloan
Kettering Cancer Center. Higher BMI was associated with
reduced cancer-specific mortality in univariable analyses
(P < 0.005), but this association was lost after adjusting for
stage and grade (P > 0.10).
Selection Bias/Collider Stratification Bias
The obesity paradox might be due to a specific form of selec-
tion bias, known as the collider stratification bias, caused dur-
ing the statistical analysis due to conditioning on a subpopu-
lation selected based on a collider variable. In turn, a collider
variable is one with at least two causes common to the risk of
the variable and the outcome of interest. For example, cancer
incidence is a collider variable because it is Bcaused^ by both
obesity and other risk factors (e.g., smoking). There is a well-
recognized inverse relationship between BMI and smoking.
Thus, cancer patients who are not obese are more likely to
have other risk factors, such as smoking, and in the analyzed
subpopulation, an inverse association is artificially generated
(or strengthened) between obesity and the other risk factors.
Additionally, Banack and Kaufman [38••] demonstrate how
confounding due to smoking is increased in the presence of
collider stratification bias. In a contrary direction, Sperrin et al.
[39••], using an equation-derived approach within a counter-
factual framework, show that the biases attributable to collider
stratification are small and cannot explain the large paradoxi-
cal relationships seen in epidemiological studies.
Detection Bias
A further dimension is detection bias. This is the co-
occurrence of two diagnoses together. Thus, for example, be-
ing overweight and obese is associated with the development
of diabetes and cardiovascular disease.Where patients present
with new diagnoses of these conditions, they undergo several
investigations, which in turn detect incidental diseases includ-
ing silent cancers—a form of Bopportunistic surveillance^.
This overestimation of the occurrence of cancer diagnosis
concurrent with a new diagnosis of diabetes is well recognized
[40]. These silent cancers might have a low-stage disease with
generally good prognosis and account for the obesity paradox
in overweight and obese patients. One approach to minimize
56 Page 4 of 8 Curr Oncol Rep (2016) 18: 56
detection bias is to adjust for tumor stage at presentation or
alternatively where the date of diagnosis of, say, diabetes is
known, use a washout of 2 years to Bbypass^ the detection
bias.
Reverse Causality
Reverse causality refers to the phenomenon that some normal-
weight patients may have previously been obese but lost
weight due to illness, here cancer. Cancer is known to cause
weight loss by loss of appetite or increased metabolic de-
mands. The extent of weight loss correlates with initial BMI
and occurs in patients with early-stage as well as late-stage
tumors [41]. The potential causal link of reverse causality with
the obesity paradox has been shown in several examples.
Thus, Gelber and colleagues [42] evaluated the relationship
between BMI and mortality in 99,253 male physicians in the
Physicians’ Health Study and initially showed a U-shaped
association with all-cause mortality, which converted to a lin-
ear relationship in their optimal model excluding men who
died within 2 years of initial assessment. Similarly, Tseng
[43] evaluated a nationally representative cohort of 89,056
Taiwanese patients with type 2 diabetes, matched with the
National Death Certificate Database, and on initial analysis
found that BMI was inversely associated with mortality from
all-cause, cancer, and diabetes complications, but after exclud-
ing patients with a follow-up duration less than 2 years, BMI
categories were not significantly prognostic for cancer-related
mortality, suggesting a bias induced by cancer-induced weight
loss.
Reverse causality is better explored and minimized by
using longitudinal data to obtain a description of the patient’s
usual weight and its trajectory up to cancer diagnosis. Weight
histories (repeated weight measurements) give a useful dimen-
sion of obesity exposure, but there is a paucity of such data.
Research to define obesity-equivalence of pack-years will be
informative. A simpler approachwhen weight histories are not
available is to include an individual’s maximum lifetime BMI
and is robust to confounding by illness-induced weight loss.
Stokes and Preston [37] have illustrated this approach demon-
strating a reduction in biases when including maximum life-
time BMI into their models. This approach is similar to eval-
uating weight change, for example, the rate of change and size
of variability over time [28, 44].
Clinical Explanations
Tumor Biology Is Less Aggressive
There are some examples where tumors among obese patients
have less aggressive characteristics compared with those
among normal-weight patients. In obese women with
endometrial cancer, there is a predominance of good
prognosis type 1 tumors compared with poor prognosis type
2 endometrial cancer. Tumors are molecularly heterogeneous,
and it is speculated that obesity is associated with less aggres-
sive biological subtypes. For renal carcinoma, obesity is asso-
ciated with more indolent molecular variants (for example,
reduced fatty acid synthase, FASN, gene expression) [12],
while in contrast, for ovarian cancer, elevated BMI is associ-
ated with good prognosis cancers (low-grade serous and
endometrioid), but within this histological type subpopula-
tion, there is a linear positive association between BMI and
mortality, which is absent in high-grade serous ovarian can-
cers [45].
Tumors Respond Better in Obese Patients
The overweight and obese state might influence treatment
outcomes, both in terms of how the tumor (changed for con-
sistency) behaves to treatment and in terms of the differential
pharmacokinetics of cancer treatment regimens. For example,
high-intra-abdominal fat volume predicts for greater doxoru-
bicin exposure and hematologic toxicities in women with
breast cancer compared with body surface area [46].
Similarly, overweight and obese patients might be differential-
ly allocated to less radical cancer surgery, though Gurunathan
and Myles [47] point out the limitations of BMI as a predictor
of peri-operative complication risk and indicate that mildly
obese and overweight patients outperform normal-weight pa-
tients after many types of surgeries.
A specific mention is worthwhile for the complex inter-
relationships between adjuvant chemotherapy (after curative
resection) and the overweight/obese state. There is a well-
recognized clinical practice among many oncologists to dose
cap chemotherapy in obese patients with body surface area
(BSA) greater than 2.0, and together with differential alloca-
tion and differential adherence to adjuvant chemotherapy,
obese patients may simply have poorer outcomes compared
with normal-weight patients because they are sub-optimally
treated. This is illustrated by Sinicrope and colleagues [48],
who examined the prognostic impact of BMI in 25,291 pa-
tients with stage II and III colon carcinoma within the
Adjuvant Colon Cancer Endpoints (ACCENT) database, a
consortium of randomized trials of 5-fluorouracil-based adju-
vant chemotherapy. With disease-free survival (DFS) as a key
outcome measure, compared with normal-weight patients,
they showed a significant reduction in DFS limited to men
with class 2 and 3 obesity (BMI ≥35.0 kg/m2) but an improved
survival for overweight and class 1 obese (BMI 25.0 to
34.9 kg/m2) men, i.e., the obesity paradox. There were differ-
ent dose-capping practices among the trials, and there was
lack of data on chemotherapy adherence by BMI status, such
that the study was unable to conclude whether or not these
confounders contributed to the differential impact of BMI
states on survival.
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Energy Reserve or Hibernation Hypothesis
A third hypothesis is that excess adipose tissue serves as a
nutrient reserve and confers a survival advantage in times of
stress, such as anti-cancer treatment. This is akin to the hiber-
nation theories in evolutional biology whereby species store
up energy in anticipation of harsh times ahead. On a parallel
note, it remains unclear if obesity drives cancer progression,
whether it is due to excess adiposity or the energy imbalance
[49].
Conclusions and Future Directions
This review has highlighted the mixed findings in studies
evaluating the obesity paradox in cancer populations. In terms
of interpreting these studies, and designing future studies on
this topic, there is a need to apply a methodological frame-
work to determine whether the obesity paradox is a true or
spurious relationship for a given setting. If a framework is not
used, mistaken interpretations can be reached. Thus, in the
cardiovascular literature, some commentators have concluded
that the obesity paradox is a true causal association arguing
that the optimum body weight is above the normal BMI range
in individuals with some chronic diseases [17].
First, where the primary interest is the effect of obesity on
survival, it is preferred to incorporate as much information
regarding the patients’ weight history, i.e., consider the pa-
tient’s BMI trajectory throughout a long period of time or
ideally through the whole life-course. Variations on this in-
clude modeling BMI at pre-, peri-, and post-diagnosis of can-
cer. An alternative is to use maximum lifetime weight and
weight variability measures.
Second, it is important to work within datasets with rich-
ness for potential confounding. The following are potential
effect modifiers or confounders of the relationship between
BMI and survival but are not always captured: smoking, hor-
monal replacement therapy, and ethnicity. Cancers diagnosed
through screening programs have better prognosis than non-
screened cancer, and in turn, obesity tends to be associated
with lower uptake rates in cancer screening.
Third, conflicting findings may be partly explained by het-
erogeneity within cancer types, the timing of when BMI was
determined, unmeasured confounders, and statistical biases.
To further understand the observed associations, directions
for future research include (i) improving the Bsubtyping^ of
cancer by better recording of staging, tumor type; (ii) improv-
ing data linkage so BMI, adiposity measures, and confound-
ing variables can readily be extracted from records and incor-
porated; and (iii) further research into the gender-specific links
of the effect of obesity and overweight on survival in cancer
populations.
It is imperative for the oncologist to interpret the observa-
tion of the obesity paradox against the above methodological
framework and avoid the misinterpretation that being obese
might be Bgood^ or Bprotective^ for cancer patients. ‘First, do
no harm’.
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